2-Aminoindane Compound Selectivity for Rapid CNS Modulation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for mental disorders such as PTSD, depression, and anxiety are slow to take effect, often requiring weeks, and many patients experience unwanted side effects or non-response, while existing drugs like SSRIs and monoamine releasers have limitations including long ramp-up times and potential for abuse.

Innovation Solution

Development of 2-aminoindane compounds that interact with serotonergic binding sites, acting as fast-acting agents with entactogenic properties, providing rapid modulation of CNS activity and minimizing dopaminergic effects to enhance empathy and reduce addictive liability.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current medications for mental disorders are used, then therapeutic effects are achieved, but the treatment takes weeks to show results

Engineering Contradiction:

Improvetherapeutic effectivenessVSAvoidramp-up time

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The patent changes the chemical structure parameters by using 2-aminoindane compounds with specific substitutions (such as 5-methoxy-2-aminoindane) to achieve rapid onset of action within minutes to hours, fundamentally altering the time parameter of therapeutic effect compared to conventional SSRIs that take weeks

Inventive Principle:

Principle #35Parameter changes

2Reliability

If existing drugs like SSRIs and monoamine releasers are used, then neurotransmitter levels are modulated, but unwanted side effects and addictive liability occur

Engineering Contradiction:

Improveneurotransmitter modulationVSAvoidside effects and abuse potential

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent applies local quality by designing compounds with specific selectivity for serotonin transporters over dopamine transporters, creating regional specificity in neurotransmitter modulation that minimizes dopaminergic side effects and addictive liability while maintaining therapeutic effectiveness

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent converts the potential harm of non-selective monoamine modulation into benefit by engineering compounds that selectively target serotonin reuptake, thereby eliminating the harmful dopaminergic effects associated with abuse potential while preserving the therapeutic benefits of serotonin modulation

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

3Speed

If non-selective monoamine releasers are used, then rapid therapeutic effects are achieved, but dopaminergic effects increase addictive liability

Engineering Contradiction:

Improveonset of actionVSAvoidaddictive liability

Core Design Contradiction:

SpeedVSObject-generated harmful factors

Solution Approach 1:

The patent changes the selectivity parameter by designing 2-aminoindane compounds with molecular features that confer preference for serotonin transporter binding over dopamine transporter binding, achieving rapid onset without the harmful dopaminergic effects that cause addiction

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS12454515B22-aminoindane compounds for mental disorders or enhancement

Publication Date: 2025.10.28 TACTOGEN INC

AI summary

The present invention discloses 2-aminoindane Formulas I and II and their pharmaceutically acceptable salts, compositions and methods of use to modulate central nervous system activity, and to treat central nervous system disorders, such as post-traumatic stress, depression, anxiety, and adjustment disorders. In certain embodiments, the compounds of the present invention can be used for entactogenic therapy in counseling sessions, as needed periodically or consistently as necessary or desired.